Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Investigating Two rTMS Strategies to Treat Cannabis Use Disorder
In this trial we will work with a group of participants who are having problems related to marijuana use (they have Cannabis Use Disorder) and who want to reduce the amount of marijuana they use or quit using marijuana completely. We are testing to see if a treatment called repetitive transcranial magnetic stimulation (rTMS) can help them achieve that goal when combined with a brief three-session counseling therapy. Participants will receive rTMS to one of two different parts of the brain (the dorsolateral prefrontal cortex--the DLPFC or the ventromedial prefrontal cortex--the vmPFC) to see if applying rTMS to one brain area is more helpful than the other brain area.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive Transcranial Magnetic Stimulation (rTMS)
Eligibility
Inclusion Criteria:
1. Participants must be able to provide informed consent and function at an intellectual
level sufficient to allow accurate completion of all assessment instruments.
2. Participants must be between the ages of 18 and 60.
3. Participants must meet DSM-5 criteria for at least moderate Cannabis Use Disorder,
with use of at least 20 out of the last 28 days.
4. Participants must express a desire to reduce cannabis use or quit.
5. Participants must have a positive UDS for cannabis during their enrollment visit
(confirming they are regular users).
6. The investigative team must believe each participant is a good study-candidate.
Exclusion Criteria:
1. Participants must not be pregnant or breastfeeding.
2. Participants must not meet moderate or severe use disorder of any other substance with
the exception of tobacco/nicotine.
3. Participants must not be on any medications that have central nervous system effects
that have changed in the past 4-weeks.
4. Participants must not have a history of/or current psychotic disorder or bipolar
disorder.
5. Participants must not have any other Axis I condition requiring current treatment.
6. Participants must not have a history of Dementia or other cognitive impairment.
7. Participants must not have active suicidal ideation, or a suicide attempt within the
past 180 days.
8. Participants must not have any contraindications to receiving rTMS or MRI (e.g. metal
implanted above the head, history of seizure, any known brain lesion).
9. Participants must not have any unstable general medical conditions.
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Study Team
650-374-0907
I'm interested
Psoriasis Clinical Trials
Investigating Two rTMS Strategies to Treat Cannabis Use Disorder
In this trial we will work with a group of participants who are having problems related to marijuana use (they have Cannabis Use Disorder) and who want to reduce the amount of marijuana they use or quit using marijuana completely. We are testing to see if a treatment called repetitive transcranial magnetic stimulation (rTMS) can help them achieve that goal when combined with a brief three-session counseling therapy. Participants will receive rTMS to one of two different parts of the brain (the dorsolateral prefrontal cortex--the DLPFC or the ventromedial prefrontal cortex--the vmPFC) to see if applying rTMS to one brain area is more helpful than the other brain area.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive Transcranial Magnetic Stimulation (rTMS)
Eligibility
Inclusion Criteria:
1. Participants must be able to provide informed consent and function at an intellectual
level sufficient to allow accurate completion of all assessment instruments.
2. Participants must be between the ages of 18 and 60.
3. Participants must meet DSM-5 criteria for at least moderate Cannabis Use Disorder,
with use of at least 20 out of the last 28 days.
4. Participants must express a desire to reduce cannabis use or quit.
5. Participants must have a positive UDS for cannabis during their enrollment visit
(confirming they are regular users).
6. The investigative team must believe each participant is a good study-candidate.
Exclusion Criteria:
1. Participants must not be pregnant or breastfeeding.
2. Participants must not meet moderate or severe use disorder of any other substance with
the exception of tobacco/nicotine.
3. Participants must not be on any medications that have central nervous system effects
that have changed in the past 4-weeks.
4. Participants must not have a history of/or current psychotic disorder or bipolar
disorder.
5. Participants must not have any other Axis I condition requiring current treatment.
6. Participants must not have a history of Dementia or other cognitive impairment.
7. Participants must not have active suicidal ideation, or a suicide attempt within the
past 180 days.
8. Participants must not have any contraindications to receiving rTMS or MRI (e.g. metal
implanted above the head, history of seizure, any known brain lesion).
9. Participants must not have any unstable general medical conditions.
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Study Team
650-374-0907
I'm interested
Dermatology Clinical Trials
Investigating Two rTMS Strategies to Treat Cannabis Use Disorder
In this trial we will work with a group of participants who are having problems related to marijuana use (they have Cannabis Use Disorder) and who want to reduce the amount of marijuana they use or quit using marijuana completely. We are testing to see if a treatment called repetitive transcranial magnetic stimulation (rTMS) can help them achieve that goal when combined with a brief three-session counseling therapy. Participants will receive rTMS to one of two different parts of the brain (the dorsolateral prefrontal cortex--the DLPFC or the ventromedial prefrontal cortex--the vmPFC) to see if applying rTMS to one brain area is more helpful than the other brain area.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive Transcranial Magnetic Stimulation (rTMS)
Eligibility
Inclusion Criteria:
1. Participants must be able to provide informed consent and function at an intellectual
level sufficient to allow accurate completion of all assessment instruments.
2. Participants must be between the ages of 18 and 60.
3. Participants must meet DSM-5 criteria for at least moderate Cannabis Use Disorder,
with use of at least 20 out of the last 28 days.
4. Participants must express a desire to reduce cannabis use or quit.
5. Participants must have a positive UDS for cannabis during their enrollment visit
(confirming they are regular users).
6. The investigative team must believe each participant is a good study-candidate.
Exclusion Criteria:
1. Participants must not be pregnant or breastfeeding.
2. Participants must not meet moderate or severe use disorder of any other substance with
the exception of tobacco/nicotine.
3. Participants must not be on any medications that have central nervous system effects
that have changed in the past 4-weeks.
4. Participants must not have a history of/or current psychotic disorder or bipolar
disorder.
5. Participants must not have any other Axis I condition requiring current treatment.
6. Participants must not have a history of Dementia or other cognitive impairment.
7. Participants must not have active suicidal ideation, or a suicide attempt within the
past 180 days.
8. Participants must not have any contraindications to receiving rTMS or MRI (e.g. metal
implanted above the head, history of seizure, any known brain lesion).
9. Participants must not have any unstable general medical conditions.
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Study Team
650-374-0907
I'm interested
Pediatric Dermatology Clinical Trials
Investigating Two rTMS Strategies to Treat Cannabis Use Disorder
In this trial we will work with a group of participants who are having problems related to marijuana use (they have Cannabis Use Disorder) and who want to reduce the amount of marijuana they use or quit using marijuana completely. We are testing to see if a treatment called repetitive transcranial magnetic stimulation (rTMS) can help them achieve that goal when combined with a brief three-session counseling therapy. Participants will receive rTMS to one of two different parts of the brain (the dorsolateral prefrontal cortex--the DLPFC or the ventromedial prefrontal cortex--the vmPFC) to see if applying rTMS to one brain area is more helpful than the other brain area.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive Transcranial Magnetic Stimulation (rTMS)
Eligibility
Inclusion Criteria:
1. Participants must be able to provide informed consent and function at an intellectual
level sufficient to allow accurate completion of all assessment instruments.
2. Participants must be between the ages of 18 and 60.
3. Participants must meet DSM-5 criteria for at least moderate Cannabis Use Disorder,
with use of at least 20 out of the last 28 days.
4. Participants must express a desire to reduce cannabis use or quit.
5. Participants must have a positive UDS for cannabis during their enrollment visit
(confirming they are regular users).
6. The investigative team must believe each participant is a good study-candidate.
Exclusion Criteria:
1. Participants must not be pregnant or breastfeeding.
2. Participants must not meet moderate or severe use disorder of any other substance with
the exception of tobacco/nicotine.
3. Participants must not be on any medications that have central nervous system effects
that have changed in the past 4-weeks.
4. Participants must not have a history of/or current psychotic disorder or bipolar
disorder.
5. Participants must not have any other Axis I condition requiring current treatment.
6. Participants must not have a history of Dementia or other cognitive impairment.
7. Participants must not have active suicidal ideation, or a suicide attempt within the
past 180 days.
8. Participants must not have any contraindications to receiving rTMS or MRI (e.g. metal
implanted above the head, history of seizure, any known brain lesion).
9. Participants must not have any unstable general medical conditions.
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Study Team
650-374-0907
I'm interested
Investigating Two rTMS Strategies to Treat Cannabis Use Disorder
In this trial we will work with a group of participants who are having problems related to marijuana use (they have Cannabis Use Disorder) and who want to reduce the amount of marijuana they use or quit using marijuana completely. We are testing to see if a treatment called repetitive transcranial magnetic stimulation (rTMS) can help them achieve that goal when combined with a brief three-session counseling therapy. Participants will receive rTMS to one of two different parts of the brain (the dorsolateral prefrontal cortex--the DLPFC or the ventromedial prefrontal cortex--the vmPFC) to see if applying rTMS to one brain area is more helpful than the other brain area.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive Transcranial Magnetic Stimulation (rTMS)
Eligibility
Inclusion Criteria:
1. Participants must be able to provide informed consent and function at an intellectual
level sufficient to allow accurate completion of all assessment instruments.
2. Participants must be between the ages of 18 and 60.
3. Participants must meet DSM-5 criteria for at least moderate Cannabis Use Disorder,
with use of at least 20 out of the last 28 days.
4. Participants must express a desire to reduce cannabis use or quit.
5. Participants must have a positive UDS for cannabis during their enrollment visit
(confirming they are regular users).
6. The investigative team must believe each participant is a good study-candidate.
Exclusion Criteria:
1. Participants must not be pregnant or breastfeeding.
2. Participants must not meet moderate or severe use disorder of any other substance with
the exception of tobacco/nicotine.
3. Participants must not be on any medications that have central nervous system effects
that have changed in the past 4-weeks.
4. Participants must not have a history of/or current psychotic disorder or bipolar
disorder.
5. Participants must not have any other Axis I condition requiring current treatment.
6. Participants must not have a history of Dementia or other cognitive impairment.
7. Participants must not have active suicidal ideation, or a suicide attempt within the
past 180 days.
8. Participants must not have any contraindications to receiving rTMS or MRI (e.g. metal
implanted above the head, history of seizure, any known brain lesion).
9. Participants must not have any unstable general medical conditions.
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Study Team
650-374-0907
I'm interested
Investigating Two rTMS Strategies to Treat Cannabis Use Disorder
In this trial we will work with a group of participants who are having problems related to marijuana use (they have Cannabis Use Disorder) and who want to reduce the amount of marijuana they use or quit using marijuana completely. We are testing to see if a treatment called repetitive transcranial magnetic stimulation (rTMS) can help them achieve that goal when combined with a brief three-session counseling therapy. Participants will receive rTMS to one of two different parts of the brain (the dorsolateral prefrontal cortex--the DLPFC or the ventromedial prefrontal cortex--the vmPFC) to see if applying rTMS to one brain area is more helpful than the other brain area.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Repetitive Transcranial Magnetic Stimulation (rTMS)
Eligibility
Inclusion Criteria:
1. Participants must be able to provide informed consent and function at an intellectual
level sufficient to allow accurate completion of all assessment instruments.
2. Participants must be between the ages of 18 and 60.
3. Participants must meet DSM-5 criteria for at least moderate Cannabis Use Disorder,
with use of at least 20 out of the last 28 days.
4. Participants must express a desire to reduce cannabis use or quit.
5. Participants must have a positive UDS for cannabis during their enrollment visit
(confirming they are regular users).
6. The investigative team must believe each participant is a good study-candidate.
Exclusion Criteria:
1. Participants must not be pregnant or breastfeeding.
2. Participants must not meet moderate or severe use disorder of any other substance with
the exception of tobacco/nicotine.
3. Participants must not be on any medications that have central nervous system effects
that have changed in the past 4-weeks.
4. Participants must not have a history of/or current psychotic disorder or bipolar
disorder.
5. Participants must not have any other Axis I condition requiring current treatment.
6. Participants must not have a history of Dementia or other cognitive impairment.
7. Participants must not have active suicidal ideation, or a suicide attempt within the
past 180 days.
8. Participants must not have any contraindications to receiving rTMS or MRI (e.g. metal
implanted above the head, history of seizure, any known brain lesion).
9. Participants must not have any unstable general medical conditions.
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Study Team
650-374-0907
I'm interested